Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyperlipidaemia and aortic valve disease.

Anne Bjørhovde Rossebø1, Terje R Pedersen

  • 1Cardiology Department, Aker University Hospital, Oslo, Norway. anne_rossebo@hotmail.com

Current Opinion in Lipidology
|July 10, 2004
PubMed
Summary

Degenerative aortic valve stenosis shares risk factors with atherosclerosis, including hyperlipidaemia. Further research is needed to confirm if lipid-lowering interventions can effectively treat this condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial.

European journal of preventive cardiology·2021
Same author

Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial.

Circulation journal : official journal of the Japanese Circulation Society·2021
Same author

Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project.

Atherosclerosis. Supplements·2021
Same author

LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial.

Atherosclerosis·2021
Same author

Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.

JAMA cardiology·2020
Same author

Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.

JAMA cardiology·2020

Area of Science:

  • Cardiovascular Medicine
  • Geriatrics
  • Pathology

Background:

  • Degenerative aortic valve stenosis is a prevalent condition in the elderly population.
  • Traditional atherosclerotic risk factors, such as hyperlipidaemia, have been implicated in its development.
  • Understanding these risk factors is crucial for developing effective interventions.

Purpose of the Study:

  • To review the role of various risk factors in degenerative aortic valve stenosis.
  • To explore the potential for therapeutic interventions targeting these risk factors.
  • To elucidate the relationship between lipid abnormalities and aortic stenosis.

Main Methods:

  • Literature review of studies investigating risk factors for degenerative aortic valve stenosis.
  • Analysis of associations between lipid profiles, inflammatory markers, and aortic stenosis.
  • Examination of animal models with cholesterol-rich diets to understand disease mechanisms.

Main Results:

  • Lipid abnormalities (e.g., high lipoprotein(a), apolipoprotein E4 allele) are associated with aortic stenosis.
  • Inflammatory markers are present in both plasma and excised aortic valves.
  • Animal studies show similarities between cholesterol-induced lesions and early-stage aortic stenosis.

Conclusions:

  • Degenerative aortic valve stenosis shares etiological factors with atherosclerosis, including hyperlipidaemia and inflammation.
  • The findings suggest that aortic stenosis may be amenable to interventions targeting lipid metabolism.
  • Randomized controlled trials are necessary to validate the efficacy of lipid-modifying therapies in patients with aortic valve stenosis.

Related Experiment Videos